Reevaluating the accelerated approval process for oncology drugs

Clinical Cancer Research

Volumn 19, Issue 11, 2013, Pages 2804-2809

  Wilson, Wyndham H ^a   Schenkein, David P ^c   Jernigan, Cheryl L ^d   Woodcock, Janet ^b   Schilsky, Richard L ^e  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c AGIOS PHARMACEUTICALS   (United States)

^d Susan G Komen for the Cure   (United States)

^e AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BORTEZOMIB; BRENTUXIMAB VEDOTIN; CARFILZOMIB; CRIZOTINIB; FLUORODEOXYGLUCOSE F 18; LAPATINIB; PERTUZUMAB; TAXANE DERIVATIVE; TRASTUZUMAB;

BREAST CANCER; COMPUTER ASSISTED TOMOGRAPHY; CRITERION VARIABLE; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HODGKIN DISEASE; HUMAN; LARGE CELL LYMPHOMA; LUNG NON SMALL CELL CANCER; MULTIPLE MYELOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW;

ANTINEOPLASTIC AGENTS; DRUG APPROVAL; HUMANS; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84878996175     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-0315     Document Type: Review

References (31)

1. Johnson JR, Ning YM, Farrell A, Justice R, Keegan P, Pazdur R. Accelerated approval of oncology products: the Food and Drug Administration experience. J Natl Cancer Inst 2011;103:636-44.
2. Mitka M. Oversight of fast-track drug approval by FDA stuck in low gear, critics say. Jama 2010;304:1773-5.
3. Mullard A. Accelerated approval dust begins to settle. Nat Rev Drug Discov 2011;10:797-8.
4. Ellenberg SS. Accelerated approval of oncology drugs: can we do better? J Natl Cancer Inst 2011;103:616-7.
5. Richey EA, Lyons EA, Nebeker JR, Shankaran V, McKoy JM, Luu TH, et al. Accelerated approval of cancer drugs: improved access to therapeutic breakthroughs or early release of unsafe and ineffective drugs? J Clin Oncol 2009;27:4398-405.
6. Krop IE, Lorusso P, Miller KD, Modi S, Yardley D, Rodriguez G, et al. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine. J Clin Oncol 2012;30:3234-41.
7. Genentech. Press Release. 2010 [cited 2013 Mar 20]. Available from: http://www.gene.com/gene/news/press-releases/display.do?method=detail&id= 12947.
8. FDA. Ado-trastuzumab emtansine approval summary. 2013 [cited 2013 Mar 15]. Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ ucm340913.htm.
9. FDA. February 8, 2011: Oncologic Drugs Advisory Committee Meeting Announcement. 2011 [cited 2013 Mar 20]. Available from: http://www.fda.gov/ AdvisoryCommittees/Calendar/ucm239360.htm.
10. de Claro RA, McGinn K, Kwitkowski V, Bullock J, Khandelwal A, Habtemariam B, et al. U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res 2012;18:5845-9.
11. FDA. Crizotinib approval summary. 2011 [cited 2013 Mar 20]. Available from: http://www.fda.gov/AboutFDA/CentersOffices/ OfficeofMedicalProductsandTobacco/CDER/ucm270058.htm.
12. FDA. Car filzomib approval summary. 2012 [cited 2013 Mar 20]. Available from: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm312945.htm.
13. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74.
14. Frei E III, Eder JP. Combination chemotherapy. In: Kufe DW, Pollock RE, Weichselbaum RR, et al., editors. Holland-Frei cancer medicine. 6th ed. Hamilton, ON, Canada: BC Decker; 2003 [cited 2013 Mar 20]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK13955/.
15. Baselga J, Cortes J, Kim SB, Im SA, Hegg R, Im YH, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109-19.
16. Blackwell KL, Burstein HJ, Storniolo AM, Rugo HS, Sledge G, Aktan G, et al. Overall survival bene fit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 2012;30:2585-92.
17. FDA. Guidance for industry: clinical trial endpoints for the approval of cancer drugs and biologics. 2007 [cited 2013 Mar 20]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/ucm071590.pdf.
18. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45:228-47.
19. FDA. Draft guidance for industry: qualification process for drug development tools. 2010 [cited 2013 Mar 20]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM230597.pdf.
20. FDA. Draft guidance for industry: pathologic complete response in neoadjuvant treatment of high-risk early-stage breast cancer: use as an endpoint to support accelerated approval. 2012 [cited 2013 Mar 20]. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/ Guidances/UCM305501.pdf.
21. Hayes DF, Bast RC, Desch CE, Fritsche H Jr, Kemeny NE, Jessup JM, et al. Tumor marker utility grading system: a framework to evaluate clinical utility of tumor markers. J Natl Cancer Inst 1996;88:1456-66. (Pubitemid 26340047)
22. Sargent DJ, Rubinstein L, Schwartz L, Dancey JE, Gatsonis C, Dodd LE, et al. Validation of novel imaging methodologies for use as cancer clinical trial end-points. Eur J Cancer 2009;45:290-9.
23. Kelloff GJ, Sigman CC. Cancer biomarkers: selecting the right drug for the right patient. Nat Rev Drug Discov 2012;11:201-14.
24. Kelloff GJ, Hoffman JM, Johnson B, Scher HI, Siegel BA, Cheng EY, et al. Progress and promise of FDG-PET imaging for cancer patient management and oncologic drug development. Clin Cancer Res 2005;11:2785-808. (Pubitemid 40525178)
25. Danila DC, Pantel K, Fleisher M, Scher HI. Circulating tumors cells as biomarkers: progress toward biomarker quali fication. Cancer J 2011;17:438-50.
26. Campana D. Minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2010;2010:7-12.
27. Timmerman JM, Vose JM, Czerwinski DK, Weng WK, Ingolia D, Mayo M, et al. Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for follicular non-Hodgkin lymphoma. Leuk Lymphoma 2009;50:37-46.
28. Corbett Dooren J. Pfizer to withdraw a cancer drug mylotarg. Wall Street J. 2010 Jun 22 [cited 2013 Mar 20]. Available from: http://online.wsj.com/ article/SB10001424052748704895204575321210108285270.html.
29. Burton T, Corbett Dooren J. Key approval yanked for avastin. Wall Street J. 2011 Nov 19 [cited 2013 Mar 20]. Available from: http://online.wsj.com/ article/SB10001424052970203699404577046041941288780.html.
30. FDA. AstraZeneca Pharmaceuticals LP; withdrawal of approval of a new drug application for IRESSA. 2012 [cited 2013 Mar 20]. Available from: www.federalregister.gov/articles/2012/04/25/2012-9944/astrazeneca- pharmaceuticals-lp-withdrawal-of-approval-of-a-new-drug-application-for-iressa.
31. Ravandi F, Estey EH, Appelbaum FR, Lo-Coco F, Schiffer CA, Larson RA, et al. Gemtuzumab ozogamicin: time to resurrect? J Clin Oncol 2012;30:3921-3.